Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
Globally, the treatment of coronary in-stent restenosis and other challenging artery disease indications is rapidly shifting toward drug-coated balloons.
- Globally, the treatment of coronary in-stent restenosis and other challenging artery disease indications is rapidly shifting toward drug-coated balloons.
- Financial Results for the Year Ended December 31, 2023
Cash and cash equivalents and marketable securities totaled $87.6 million as of December 31, 2023. - Net loss for 2023 was $49.1 million, or ($1.48) per share, compared with a net loss of $33.6 million, or ($2.24) per share, for 2022.
- Net loss for the year-ended 2023 included non-cash stock-based compensation expense of $7.6 million, compared with $3.4 million for the same period in 2022.